CRSP240726C64000
- 0.08
- +0.03+60.00%
CRISPR Therapeutics Newsroom
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
CRISPR Therapeutics Stock Is Approaching Its 52-Week Low
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
Agilent to Acquire North American CDMO BIOVECTRA
Institutional Investors Must Be Pleased After a 8.9% Gain Last Week That Adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) One-year Returns
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Ark's Cathie Wood Blasts Big Tech. She Prefers Palantir and These Other Stocks.
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?
Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note